Lung cancer: adding bevacizumab to limertinib vs limertinib alone
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding a second drug (bevacizumab) to a first-line EGFR-targeted pill (limertinib) helps people with a specific type of lung cancer (non-squamous NSCLC) live longer and control their cancer better. You must have an EGFR mutation and a high PD-L1 score to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that has spread or come back, and can't be removed with surgery.
- Your tumor must have an EGFR mutation, either an exon 19 deletion or an L858R mutation.
- Your tumor's PD-L1 score must be 25 or higher, based on a lab test.
- You should be able to care for yourself (a score of 0 or 1 on the ECOG scale).
- You must not have had prior treatment with EGFR-targeted pills or anti-angiogenic drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
This trial tests a new drug (QL1706) combined with bevacizumab, with or without chemotherapy, for people with advanced non-squamous non-small cell lung cancer that has grown after prior immunotherapy. It aims to see if this combination can help control the cancer.
This trial tests a new combination of three drugs for people with advanced non-small cell lung cancer that has grown despite previous immunotherapy. The goal is to see if adding these drugs can help control the cancer better.
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
This trial tests a new combination of immunotherapy (QL1706), chemotherapy, and bevacizumab (a drug that stops blood vessel growth) for people with a specific type of non-small cell lung cancer that has stopped responding to targeted therapy. It may help shrink tumors or slow their growth.
Hear when a new EGFR Mutation Positive Advanced Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.